Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947124 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04947124 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 3 participants.
The verdict
NCT04947124, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
Interventions
- DRUG QLS-101ophthalmic solution 1%
- DRUG QLS-101ophthalmic solution 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2022-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04947124
The ClinicalTrials.gov registry entry for NCT04947124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QLS-101ophthalmic solution 1% is the first listed.
NCT04947124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04947124 about?
NCT04947124 is a clinical study titled "A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101". Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
What is the current status of trial NCT04947124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-10-19. Estimated completion is 2022-08-01.
What interventions are being tested in trial NCT04947124?
The interventions under investigation include: QLS-101ophthalmic solution 1% (DRUG), QLS-101ophthalmic solution 2% (DRUG).
Who is sponsoring clinical trial NCT04947124?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.